DAIC

APRIL 18, 2024

Based on continuous monitoring of early recurrence of atrial tachyarrhythmia immediately after patients have undergone atrial fibrillation ablation, Musat et al. Early recurrence of atrial tachyarrhythmia (ERAT) is commonly seen following catheter ablation of AF, with reported incidences of up to 61% in the first three months.

Atrial Fibrillation 111

Atrial Fibrillation Ablation Heart Rhythm Article 111

Journal of Cardiovascular Electrophysiology

MARCH 17, 2025

Distribution Variance of Focal Atrial Tachycardia Foci and Long-Term Outcomes After Ablation. We aimed to evaluate age differences in foci and factors influencing recurrence after radiofrequency catheter ablation in adult and juvenile patients with FAT. After a mean follow-up of 47.2 months, FAT recurred in 57 patients.

Tachycardia 40

Tachycardia Ablation Outcomes Tricuspid 40

DAIC

APRIL 9, 2024

An international consensus statement on how to treat atrial fibrillation with catheter or surgical ablation has been published in EP Europace, a journal of the European Society of Cardiology (ESC), and was recently presented at EHRA 2024, a scientific congress held April 7-9 in Berlin, Germany. Image courtesy: European Society of Cardiology.

Atrial Fibrillation 105

Atrial Fibrillation Ablation Heart Rhythm Blood Clot 105

American College of Cardiology

FEBRUARY 23, 2024

What is the incidence of the embolic and bleeding complications in relation to pre- and post- periprocedure antithrombotic regimens in patients undergoing ventricular arrhythmia radiofrequency ablation (RFA)?

Arrhythmia 65

Arrhythmia Ablation Embolism Stroke 65

DAIC

MAY 18, 2024

During its Annual Conference, HRS 2024, the Heart Rhythm Society (HRS) announced findings from three new studies demonstrating the safety and efficacy of pulsed field ablation (PFA), a nonthermal ablation treatment for patients with atrial fibrillation (AF). See full findings from the FARADISE, admIRE Study, and Advent Trial here.

Heart Rhythm 105

Heart Rhythm Atrial Fibrillation Ablation Quality of Life 105

Frontiers in Cardiovascular Medicine

JANUARY 21, 2025

Atrial fibrillation is the most prevalent arrhythmia with a lifetime risk of nearly 30%. It can be associated with reduced quality of life and complications such as heart failure and stroke. Pulmonary vein isolation (PVI) is the most effective treatment for rhythm control. It has initially been performed with fluoroscopic catheter guiding.

Atrial Fibrillation 52

Atrial Fibrillation Quality of Life Ablation Electrophysiology 52

DAIC

DECEMBER 29, 2023

Outcomes of ablation with the FARAPULSE PFA System – a nonthermal treatment in which electric fields selectively ablate heart tissue – will be compared to outcomes following use of anti-arrhythmic drug (AAD) therapy, which is commonly prescribed for patients living with persistent AF. The company now anticipates U.S.

Atrial Fibrillation 115

Atrial Fibrillation Ablation Atrial Flutter Blood Clot 115

American College of Cardiology

FEBRUARY 19, 2025

In this weeks View, Dr. Eagle looks at arrhythmia recurrence and rhythm control after catheter ablation for atrial fibrillation. He then discusses long-term outcomes in transthyretin amyloid cardiomyopathy in patients treated with tafamidis.

Arrhythmia 58

Arrhythmia Cardiomyopathy Ablation AFIB 58

DAIC

FEBRUARY 2, 2024

a global leader in cardiac arrhythmia treatment and part of Johnson & Johnson MedTechi , revealed findings from a company-funded study of real-world data. Biosense Webster's zero fluoroscopy workflow is the first and only such workflow available in a radiofrequency (RF) cardiac ablation device.

Ablation 105

Ablation Atrial Fibrillation AFIB Heart Rhythm 105

HeartRhythm

JANUARY 8, 2025

Brugada syndrome (BrS) is a genetic heart disease that predisposes individuals to ventricular arrhythmias and sudden cardiac death. Although implantable cardioverter-defibrillators (ICDs) and quinidine are primary treatments, recurrent BrS-triggered ventricular arrhythmias can persist.

Sudden Cardiac Death 73

Sudden Cardiac Death Ablation Defibrillator Arrhythmia 73

DAIC

JANUARY 18, 2024

milla1cf Thu, 01/18/2024 - 14:21 January 18, 2024 — Abbott announced the first global procedures have been conducted using the company's new Volt Pulsed Field Ablation (PFA) System to treat patients battling common abnormal heart rhythms such as atrial fibrillation (AFib).

Heart Rhythm 105

Heart Rhythm Ablation AFIB Chest Pain 105

Medical Xpress - Cardiology

APRIL 10, 2024

The first randomized trial to investigate preventive ablation of a potential arrhythmogenic substrate associated with coronary chronic total occlusion (CTO) in patients at high risk of ventricular arrhythmias (VAs) reduces the risk of appropriate implantable cardioverter-defibrillator (ICD) therapy and unplanned hospitalization in patients with no (..)

Ablation 74

Ablation Hospital Tachycardia Defibrillator 74

Frontiers in Cardiovascular Medicine

DECEMBER 14, 2023

This study investigated the association between concurrent typical atrial flutter and cavotricuspid isthmus (CTI) ablation and the recurrence of atrial arrhythmia. The data were obtained from a multicenter registry of cryoballoon ablation for AF ( n  = 2,689). All the patients with typical atrial flutter underwent CTI ablation.

Atrial Flutter 64

Atrial Flutter Atrial Fibrillation Ablation Arrhythmia 64

HeartRhythm

APRIL 30, 2024

Options for controlling ventricular arrhythmias (VA) are limited when radiofrequency catheter ablation (RFA) fails or is not possible. Coronary venous ethanol ablation (CVEA) is a novel therapy whose role for VA refractory to RFA is not well defined.

Ablation 40

Ablation Arrhythmia 40

Frontiers in Cardiovascular Medicine

JANUARY 15, 2024

Background Catheter ablation (CA) for symptomatic atrial fibrillation (AF) offers the best outcomes for patients. Despite the benefits of CA, a significant proportion of patients suffer a recurrence; hence, there is scope to potentially improve outcomes through technical innovations such as ablation index (AI) guidance during AF ablation.

Ablation 64

Ablation Atrial Fibrillation BMI Arrhythmia 64

Journal of Cardiovascular Electrophysiology

NOVEMBER 29, 2023

However, the incidence of ventricular arrhythmias (VAs) is high in this population, both in the acute and delayed phases after implantation. LVAD patients presenting VAs refractory to antiarrhythmic therapy and catheter ablation procedures are not rare. In such patients, treatment options are extremely limited.

Arrhythmia 75

Arrhythmia Heart Failure Ablation Outcomes 75

HeartRhythm

FEBRUARY 8, 2025

Pulsed field ablation (PFA) is a promising novel method of atrial ablation with preclinical data suggesting it to be a viable option for ventricular arrhythmias.

Arrhythmia 40

Arrhythmia Ablation 40

DAIC

MARCH 28, 2024

a global leader in cardiac arrhythmia treatment and part of Johnson & Johnson MedTec h i , announced the submission of the VARIPULSE Platform for Premarket Approval Application (PMA) to the U.S. 1,ii For patients who had received ablation, median procedure and fluoroscopy times were 90.0 Food & Drug Administration ( FDA ).

Atrial Fibrillation 110

Atrial Fibrillation AFIB Ablation Pulmonary 110

HeartRhythm

APRIL 30, 2024

The safety and effetiveness of electroporation/point by point pulsed field ablation (PP PFA) as emerging technoloy for catheter ablation of ventricular arrhythmias has been described till now only in case reports.

Arrhythmia 40

Arrhythmia Ablation 40

HeartRhythm

APRIL 30, 2024

Comparative efficacy and safety data on the efficacy of radiofrequency ablation (RFA) versus pulsed field ablation (PFA) to target common idiopathic left ventricular arrhythmia (LV-Vas) locations are lacking

Ablation 40

Ablation Arrhythmia 40

DAIC

JULY 24, 2024

Volta Medical has announced it has entered into a Joint Development Agreement with GE Healthcare to enhance arrhythmia procedures with artificial intelligence (AI)-driven electrophysiology technologies. Our mission to combat complex heart rhythm diseases relies on optimizing interoperability. The company has obtained U.S.

Atrial Fibrillation 105

Atrial Fibrillation AFIB Ablation Technology 105

Frontiers in Cardiovascular Medicine

JANUARY 31, 2024

Background Pulmonary vein isolation with wide antral ablation leads to better clinical outcomes for the treatment of atrial fibrillation, but the isolation lesion is invisible in conventional cryoballoon ablation. The primary outcome was a clinical recurrence of documented atrial arrhythmias for >30 s during the 1-year follow-up.

Atrial Fibrillation 64

Atrial Fibrillation Ablation Pulmonary Outcomes 64

Frontiers in Cardiovascular Medicine

JANUARY 16, 2024

Introduction Catheter ablation is an effective and safe strategy for treating atrial fibrillation patients. Nevertheless, studies on the long-term outcomes of catheter ablation in patients with dilated cardiomyopathy are limited. Among the catheter ablation group, 58.7% ( n  = 27) had persistent atrial fibrillation.

Atrial Fibrillation 64

Atrial Fibrillation Ablation Cardiomyopathy Heart Failure 64

American College of Cardiology

DECEMBER 2, 2024

When pulsed field ablation (PFA) achieved European CE mark approval in January 2021 and U. Food and Drug Administration (FDA) approval in December 2023, it opened up the proverbial Pandora's Box for treating not only atrial fibrillation (AFib), but also ventricular arrhythmias.

Arrhythmia 40

Arrhythmia Ablation Atrial Fibrillation AFIB 40

American College of Cardiology

DECEMBER 20, 2024

Does the finding of structural abnormalities on the papillary muscles have an association with site of origin of arrhythmias? Can multimodality imaging be of benefit in planning ablation procedures?

Arrhythmia 49

Arrhythmia Ablation Article 49

HeartRhythm

APRIL 30, 2024

This study investigates radiofrequency (RF) lesions that acutely elicit arrhythmia change points (RF-CPs) early in the AF ablation procedure, and explores how this information may guide more efficient ablation.

Ablation 40

Ablation Arrhythmia 40

HeartRhythm

MARCH 2, 2025

Attempted catheter manipulation via the retrograde aortic approach carries a risk of aortic dissection (AD) during catheter ablation.

Aortic 40

Aortic Ablation Arrhythmia 40

HeartRhythm

SEPTEMBER 4, 2024

Vascular access site complications are the most frequent complications of percutaneous catheter ablation (CA) of ventricular arrhythmias (VAs). Whether arterial/venous vascular closure devices (VCDs) prevent vascular complications is unknown.

Arrhythmia 40

Arrhythmia Ablation 40

European Journal of Heart Failure

FEBRUARY 25, 2025

Overview of the study population and effects observed after catheter ablation for atrial fibrillation. Herein we describe the effects of catheter ablation on AF burden, arrhythmia recurrences, and ventricular function in end-stage HF. to 39.18.3% ( p <0.001) following ablation. PVI, pulmonary vein isolation.

Atrial Fibrillation 40

Atrial Fibrillation Ablation Heart Failure Arrhythmia 40

Circulation: Arrhythmia and Electrophysiology

MARCH 20, 2025

Circulation: Arrhythmia and Electrophysiology, Ahead of Print.

Arrhythmia 40

Arrhythmia Electrophysiology Ablation Circulation 40

HCPLive

JANUARY 8, 2024

Randomized trial data shows colchicine administered following catheter ablation did not reduce atrial arrhythmia recurrence or associated clinical events.

Arrhythmia 52

Arrhythmia Ablation 52

HeartRhythm

APRIL 30, 2024

Arrhythmias are common in patients with hypertrophic cardiomyopathy (HCM) and are associated with increased morbidity and mortality. Ventricular arrhythmias (VA) are less common compared to supraventricular arrhythmias yet are associated with worse outcomes in this patient population.

Arrhythmia 40

Arrhythmia Cardiomyopathy Ablation Outcomes 40

Journal of Cardiovascular Electrophysiology

OCTOBER 14, 2024

Abstract Background The formation of transmural lesions is necessary for the ablation of persistent atrial fibrillation (prAF). Ablation index (AI) and generator impedance drop (ID) predict lesion size but their correlation with long-term outcomes in prAF is not known. 013 (arrhythmia-free survival of 67% vs. 52%).

Arrhythmia 40

Arrhythmia Ablation Atrial Fibrillation Outcomes 40

HeartRhythm

APRIL 30, 2024

Accurate interpretation of the intracardiac electrogram (EGM) is essential to the successful ablation of idiopathic focal ventricular arrhythmias (VA). Early sharp distal bipolar EGM (biEGM), which may signify the initial activation of focal VA, is often targeted, but in an empiric fashion rather than quantitative terms.

Arrhythmia 40

Arrhythmia Ablation 40

Frontiers in Cardiovascular Medicine

DECEMBER 18, 2023

Background Cryoballoon ablation (CBA) and laser balloon ablation (LBA) are two innovative ways for the treatment of atrial fibrillation (AF). This study aimed to evaluate the efficacy and safety of cryoballoon ablation and laser balloon ablation in patients with AF.

Atrial Fibrillation 64

Atrial Fibrillation Ablation Innovation Arrhythmia 64

HeartRhythm

AUGUST 13, 2024

Atrial arrhythmias (AA), particularly atrial fibrillation (AF), are prevalent in CA and may impact long-term cardiovascular outcomes, prompting an investigation into early rhythm management strategies.2 2 However, a significant gap in understanding the safety and efficacy of AA ablation in these patients remains.

Arrhythmia 40

Arrhythmia Ablation Atrial Fibrillation Outcomes 40

HeartRhythm

APRIL 30, 2024

Ventricular arrhythmias (VA) of Posterior-Superior Process (PSP) origin are challenging to identify and ablate. Ablation from the right atrium has been described with variable ECG characteristics, but it is unclear what ECG findings may predict safe and effective ablation of the anterior coronary sinus (CS) os.

Ablation 40

Ablation Arrhythmia 40